Pieris Pharmaceuticals GmbH – Trademark Portfolio
Entity Type: 27
Pieris Pharmaceuticals GmbH holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include PIERIS, MABCALIN, and ANTICALIN.
Zeppelinstrasse 3
85399 Hallbergmoos
Showing of trademarks Trademarks
Trademark Classifications
Pieris Pharmaceuticals GmbH's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Pieris Pharmaceuticals GmbH have?
Pieris Pharmaceuticals GmbH has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.
What trademark classes does Pieris Pharmaceuticals GmbH file in?
Pieris Pharmaceuticals GmbH files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Pieris Pharmaceuticals GmbH's most well-known trademarks?
Pieris Pharmaceuticals GmbH's registered trademark portfolio includes well-known marks such as PIERIS, MABCALIN, and ANTICALIN. These are among 3 currently registered trademarks in the portfolio.
What is Pieris Pharmaceuticals GmbH's trademark registration success rate?
Pieris Pharmaceuticals GmbH has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.